InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,708.75
(
-0.93%
)
US TECH 100
19,239.16
(
-1.45%
)
Dow Jones
42,156.97
(
-0.41%
)
Brent Oil
74.60
(
3.63%
)
Bitcoin
60,843.63
(
-3.93%
)
Post# of 567
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

TenaciousD

Send PM Follow Ignore
Followers 15
Posts 1858
Boards Moderated 1
Alias Born 09/29/2006

TenaciousD

Re: peewee post# 262

Friday, 01/15/2010 3:56:06 PM

Friday, January 15, 2010 3:56:06 PM

Post# of 567
lol I stay because of this ! If approved, ANX-530 threatens to take market share away from several bigger pharmaceutical companies, including GlaxoSmithKline. This could mean a huge upside to the current share price, especially since the Company has no debt and a low float, as well as millions in cash on hand. Among ADVENTRX's top institutional holders are Carl Icahn's Icahn Capital Management, Renaissance Technologies, UBS AG, the Bank of New York Mellon and Barclay's Global Investors. Beacon Equity Research has the stock listed as "Bullish."

Have a great weekend bbb

D

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up